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ORIGINAL ARTICLE
MicroRNA-375 inhibits tumour growth and metastasis
in oesophageal squamous cell carcinoma through
repressing insulin-like growth factor 1 receptor
Kar Lok Kong,1,2 Dora Lai Wan Kwong,1,2 Tim Hon-Man Chan,1,2 Simon Ying-Kit Law,3
Leilei Chen,1,2 Yan Li,1,2 Yan-Ru Qin,4 Xin-Yuan Guan1,2,5
ABSTRACT
Background To understand the involvement of micro-
RNA (miRNA) in the development and progression of
oesophageal squamous cell carcinoma (ESCC), miRNA
profiles were compared between tumour and
corresponding non-tumour tissues.
Methods miRCURY LNA array was used to generate
miRNA expressing profile. Real-time quantitative PCR
was applied to detectthe expression of miR-375 in ESCC
samples and its correlation with insulin-like growth factor
1 receptor (IGF1R). Methylation-specific PCR was used
to study the methylation status in the promoter region of
miR-375. The tumour-suppressive effect of miR-375 was
determined by both in-vitro and in-vivo assays.
Results The downregulation of miR-375 was frequently
detected in primary ESCC, which was significantly
correlated with advanced stage (p¼0.003), distant
metastasis (p<0.0001), poor overall survival (p¼0.048)
and disease-free survival (p¼0.0006). Promoter
methylation of miR-375 was detected in 26 of 45
(57.8%) ESCC specimens. Functional assays
demonstrated that miR-375 could inhibit clonogenicity,
cell motility, cell proliferation, tumour formation and
metastasis in mice. Further study showed that miR-375
could interact with the 39-untranslated region of IGF1R
and downregulate its expression. In clinical specimens,
the expression of IGF1R was also negatively correlated
with miR-375 expression (p¼0.008).
Conclusions This study demonstrates that miR-375 has
a strong tumour-suppressive effect through inhibiting the
expression of IGF1R. The downregulation of miR-375,
which is mainly caused by promoter methylation, is one
of the molecular mechanisms involved in the
development and progression of ESCC.
Oesophageal cancer is the sixth most common
cause of death and eighth most common cancer in
the world.1 Oesophageal cancer can be divided into
two main forms: oesophageal squamous cell carci-
noma (ESCC) and adenocarcinoma. Adenocarci-
noma is common in western countries while
ESCC is predominant in east Asia, especially in
China.2 The pathogenesis of oesophageal cancer
still remains unclear although chronic irritation,
inflammation and increased cell turnover, which
may be caused by gastroesophageal reflux or
smoking, have been associated with the carcino-
genic process.1 In addition, genetic predisposition is
another important aetiological factor. Risk et al3
showed that genomic instability at chromosome
17q25 predisposes patients to ESCC. Despite
advances in the diagnosis and treatment of this
cancer, the 5-year overall survival rate is still less than
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Significance of this study
What is already known about this subject?
< miR-375 is shown to be involved in glucose
regulation of insulin gene expression and b-cell
growth.
< Recent profile studies showed that miR-375 is
downregulated in gastric cancer and hepatocel-
lular carcinoma implying the microRNA may
play an important role in cancer.
< The downregulation of miR-375 may be related
to the expression of b-catenin genes in
hepatocellular carcinoma.
What are the new findings?
< miR-375 is strongly downregulated in ESCC,
which associated with advanced stage, distant
metastasis, poor overall and disease-free
survival of ESCC patients.
< By methylation-specific PCR and BGS, we
demonstrated that the downregulation of miR-
375 is caused by the hypermethylation of the
promoter region.
< Ectopic expression of miR-375 is sufficient to
inhibit tumour cell growth and metastasis in
vitro and in vivo. miR-375 may be an important
tumour-suppressive miRNA in ESCC.
< miR-375 directly targets IGF1R indicating that it
may have significant impact on the Akt
pathway. In addition, we showed that the
expression of miR-375 is negatively correlated
with the expression of IGF1R in eight ESCC cell
lines and 60 pairs of ESCC samples.
How might it impact on clinical practice in the
foreseeable future?
< This study demonstrated that miR-375 plays
a significant role in ESCC tumour cell growth and
metastasis by inhibiting an important gene,
IGF1R, indicating thatmiR-375may be a potential
therapeutic target for ESCC patients. In addition,
the downregulation of miR-375 correlated with
poor overall and disease-free survival suggesting
that miR-375 can be a novel biomarker to
improve the management of ESCC patients.
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14%.4 Therefore, there is a great need to discover more biomarkers
and therapeutic targets for oesophageal cancer patients.
Micro-RNA (miRNA) are a class of single-stranded, non-coding
RNA only 17e25 ribonucleotides long.5 They are transcribed by
RNA polymerase II in hairpin structures and are processed by
RNAse III Drosha into long pre-miRNA. The precursors are then
processed by RNAse III Dicer to be mature miRNA, which are
able to bind to the 39-untranslated region (UTR) of target
messenger RNA through completelt or partially complementarily
causing degradation or translation repression, respectively.6 By
downregulating the target mRNA, miRNA play important roles
in the regulation of important processes such as proliferation,
differentiation, apoptosis and development.7 Several miRNA have
been reported in the development of ESCC. miR-21 has been
reported to be frequently upregulated in ESCC cell lines and
tissues, which regulates cell proliferation and invasion through
suppressing PTEN and PDCD4.8 On the other hand, miR-203was
reported to be downregulated in ESCC.9 Nevertheless, further
knowledge about the molecular mechanisms of ESCC miRNA is
needed to provide deeper insights for better therapeutic oppor-
tunities for ESCC patients. In the present study, a microarray
strategy was applied to identify differentially expressed miRNA
in ESCC cells by comparing miRNA profiles between tumour and
paired non-tumour tissues. Twenty-two differentially expressed
miRNA were detected. The tumour-suppressing function and
mechanism of miR-375, which was frequently downregulated in
ESCC, was further characterised.
MATERIALS AND METHODS
ESCC cell lines and clinical samples
Six Japanese ESCC cell lines (KYSE30, KYSE140, KYSE180,
KYSE410, KYSE510 and KYSE520) were obtained from DSMZ,
the German Resource Centre for Biological Material.10 The
Chinese ESCC cell line (EC109) and HKESC1 were kindly
provided by Professor Tsao and Professor Srivastava (University
of Hong Kong). All ESCC cell lines were regularly authenticated
by checking the morphology and were tested for the absence of
mycoplasma contamination (MycoAlert, Lonza, Rockland, ME,
USA). Human ESCC samples were collected directly after
surgical resection at Queen Mary Hospital (University of Hong
Kong, Hong Kong) and Linzhou Cancer Hospital (Henan,
China). All samples were immediately frozen in liquid nitrogen
and stored at e808C or fixed in 10% formalin for paraffin
embedding. Samples used in this study were approved by the
committees for ethical review of research at the University of
Hong Kong and the University of Zhengzhou.
miRCURY LNA array analysis
Total RNA were extracted from five pairs of ESCC tumour and
corresponding non-tumour samples using the mirVana miRNA
isolation kit (Ambion, Austin, Texas, USA). Microarray chip
analysis was performed and analysed by Exiqon (Vedbaek,
Denmark). Before the microarray analysis, RNA quality control
was guaranteed by checking the RNA integrity numbers, which is
an algorithm measuring the quality of RNA performed by the
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara,
California, USA) at the University of Hong Kong. All the samples
had an RNA integrity number greater than 7.0. The fold change
was calculated by comparing the expression of miRNA in ESCC
tumours pool and normal tissues pool in a log2 format.
Real-time quantitative PCR
Total RNA was extracted from cultured cells or frozen tissues
using TRIzol reagent (Invitrogen, Carlsbad, California, USA)
and 2 mg RNA was reverse-transcribed using the Advantage
RT-PCR kit (Clontech Laboratories, Inc., Mountain View,
California, USA) for first strand complementary DNA synthesis.
Quantitative PCR was then carried out with primers for
miR-375, SNORD48, 18s rRNA and IGF1R (see supplementary
table 1, available online only) with SYBR in the 7900 HT real-
time PCR System (Applied Biosystems, Carlsbad, California,
USA) following standard quantitative PCR protocol. Briefly,
quantitative PCR started with the incubation of samples at 508C
for 2 min followed by 958C for 10 min. Following this, quanti-
tative PCR was repeated for 40 cycles with incubation at 958C
for 15 s followed by at 608C for 1 min. The expression level was
normalised against endogenous SNORD48 and 18s rRNA for
miR-375 and other tested genes, respectively.
5-Aza-29-deoxygcitidine treatment
KYSE30 and KYSE510 (23105) cells were seeded and treated
with 5-aza-29-deoxygcitidine (50 mm and 100 mm; Sigma-Aldrich
Corporation, St Louis, Missouri, USA). Cells were incubated for
72 h with a change of culture medium every 24 h.
Promoter methylation analysis
Genomic DNAwas extracted and followed by bisulphite treatment
and then studied by methylation-specific PCR as previously
described.11 Bisulphite genomic sequencing (BGS) was also
performed for bisulphited DNA. Methylation-specific PCR and BGS
primers are listed in supplementary table 1 (available online only).
Tumour-suppressive function of miR-375
miR-375 precursor and miR-375 inhibitor were purchased from
Origene (Rockville, Maryland, USA) and Dharmacon (Lafayette,
Colorado, USA), respectively (see supplementary table 2, avail-
able online only). According to the clinical characteristics shown
in the study performed by Shimada et al,10 the tumours from
KYSE30 and KYSE510 invaded contiguous structures and thus
they may contain invasive properties. Moreover, Shimada et al10
confirmed that KYSE30 can form tumour in nude mice. There-
fore, miR-375 precursor and miR-375 inhibitor were then stably
Table 1 Differentiated dysregulation of miRNA in ESCC
miRNA Fold change
Upregulated
hsa-miR-424 3.34
hsa-miR-422a 3.06
hsa-miR-199a-5p 2.51
hsa-miR-199a-3p/hsa-miR-199b-3p 2.37
hsa-miR-181a 2.24
hsa-miR-21 2.23
hsa-miR-455-3p 2.11
hsa-miR-665 2.07
hsa-miR-483-5p 2.04
hsa-miR-127-3p 2.00
Downregulated
hsa-miR-375 5.38
hsa-miR-194 3.45
hsa-miR-215 3.03
hsa-miR-192 2.65
hsa-miR-203 2.51
hsa-miR-1249 2.29
hsa-miR-29b 2.06
hsa-miR-1281 2.05
hsa-miR-9 2.03
hsa-miR-126 2.02
hsa-miR-142-5p 2.01
hsa-miR-1 2.01
ESCC, oesophageal squamous cell carcinoma.
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and transiently transfected, respectively, into KYSE30
and KYSE510 cells using Lipofectamine 2000 (Invitrogen).
Stable miR-375 overexpressing clones (KYSE30-375+ or KYSE510-
375+) and empty vector transfected-cells (KYSE30-vector or
KYSE510-vector) were selected by using Geneticin (Invitrogen) at
a concentration of 500 mg/ml. Individual clones were
selected after 3 weeks and the expression was confirmed by
quantitative PCR. Transient transfectants miR-375 inhibited
clones (KYSE30-375e or KYSE510-375e) and inhibitor negative
controls (KYSE30-control and KYSE510-control) were transfected
for further study. For foci formation assay, 500, 1000 and 2000
cells (KYSE30-vector, KYSE30-375+, KYSE510-vector or
KYSE510-375+) were seeded in six-well plates. Surviving colonies
(>50 cells per colony) were counted with Giemsa staining after
7 days in culture. Cell proliferation assay and colony formation in
soft agar were carried out as described previously.11
For in-vivo study, 23106 miR-375-expressing cells (KYSE30-375
+ or KYSE510-375+) and empty vector cells (KYSE30-vector or
KYSE510-vector) were injected subcutaneously into the right
and left dorsal flank, respectively, of nude mice (five mice per
group). Over a 4-week period, tumour formation in nude mice
was observed by measuring the tumour volume calculated by the
formula V¼0.53L3W2. Tumours were then excised and
embedded in paraffin for haematoxylin and eoson and immuno-
histochemistry analysis. All animal experiments were approved
by the Committee on the Use of Live Animals in Teaching and
Research (CULATR), the University of Hong Kong.
Cell motility and invasion assay
Wound-healing assay and invasion assay were performed as
described previously.11 Briefly, for wound-healing assay, wound
closure was observed by taking photos under a microscope at 0, 24
and 48 h after scratching. Invasion was performed with Matrigel
(ECM; Chemicon International, Temecula, California, USA)
following the manufacturer ’s instructions. Photographs of three
randomly selected fields of the fixed cells were taken and cells were
counted. Experiments were repeated three times independently.
Metastasis assay in SCID mice
Briefly, 23105 cells (four groups including KYSE30-vector,
KYSE30-375+, KYSE510-vector and KYSE510-375+) were
injected intravenously through the tail vein into 5e6-week-old
severe combined immunodeficient (SCID-Beige) mice (five mice
per group). After 12 weeks, the number of tumour nodules
formed on the liver surfaces was counted. Lungs and livers were
excised and embedded in paraffin for further study.
Dual-luciferase reporter assay
A 301-bp fragment from the 39-UTR of the IGF1R gene (position
7124e7424) containing the binding sequences of miR-375 was
cloned into pGL3 Basic vector (Promega, Madison, Wisconsin,
USA). Reverse-sense of the fragmentswas also cloned by reversing
the sequences of the 301-bp fragment. pGL3-Control vector
(Promega) was used as a positive control. Stable miR-375 over-
expressing clones (KYSE30-375+ and KYSE510-375+) were then
Figure 1 Downregulation of miR-375
in oesophageal squamous cell
carcinoma (ESCC), which is associated
with poor prognosis. (A) Validation of
two most differentially upregulated
(miR-424 and miR-422a) and
downregulated (miR-375 and miR-194)
miRNAs in tumour (T) and
corresponding non-tumour (N) pairs
used for microarray analysis.
Expression of mir-375 was presented in
log10 scale and was normalised against
an endogenous control SNORD48. (B)
Downregulation of miR-375 was
observed in eight ESCC cell lines.
SNORD48 was used as an internal
control. N, pool of non-tumourous
tissues. (C) miR-375 was significantly
downregulated in 60 primary ESCC from
Hong Kong and (D) 45 primary ESCC
from Henan compared with their
corresponding non-tumour tissues.
Expression was shown in log10 scale
and was normalised against an
endogenous control SNORD48. (E)
Downregulation of miR-375 was
significantly associated with poorer
overall survival and (F) disease-free
survival.
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transfected with the reporter constructs containing either the
target binding sequence of IGF1R (sense) or the reversed sequence
of IGF1R (reverse-sense). Firely and Renilla luciferase signals
were determined by the Dual-LUciferase assay kit (Promega).
Western blot analysis
Western blotting was performed according to the standard
protocol with antibodies IGF1R (Novus Biologicals, Littleton,
Colorado, USA) and proliferating cell nuclear antigen (PCNA)
(Santa Cruz Biotechnology, Santa Cruz, California, USA). b-Actin
(Santa Cruz Biotechnology) was used as the loading control.
Statistical analsysis
Statistical analysis was carried out using SPSS 16.0 for Windows.
Student’s t test was used to analyse the results expressed as
mean6SD. The c2 test or Fisher ’s exact test was used to analyse
the association of miR-375 expression and clinical-pathological
parameters. The survival curves were plotted by using
KaplaneMeier analysis. Differences were considered significant
when the p value was less than 0.05.
RESULTS
miRNA profiling in human ESCC
To investigate the roles of miRNA in ESCC, miRCURY LNA array
(Exiqon) containing 850 humanmiRNAwas performed to compare
miRNA profiles between ESCC tumours and their corresponding
non-tumour tissues pooled from five primary ESCC cases from
Hong Kong. Among the 850 miRNA probes, the microarray
detected 384 miRNA in our ESCC pairs. With the twofold cut-off
point, 22 differentially expressed miRNA (10 upregulated and 12
downregulated) were detected in ESCC tumour tissues compared
with their non-tumour counterparts (table 1). The microarray
results were validated with quantitative PCR by confirming the
expression of two most upregulated (hsa-miR-424 and hsa-miR-
422a) and downregulated (hsa-miR-375 and hsa-miR-194) miRNA
in the same five pairs of human ESCC pool (figure 1A).
miR-375 is frequently downregulated in ESCC
In this study, hsa-miR-375, which has the largest absolute fold
change in the miRCURY LNA array, was further characterised.
Quantitative PCR was performed to confirm further the
expression of miR-375 in eight ESCC cell lines and 60 pairs of
primary ESCC from Hong Kong. Consistent with the miRCURY
Table 2 Association of miR-375 downregulation with
clinicopathological features of 60 ESCC patients
Clinicopathological
features Total case (%)
miR-375 expression
p ValueNegative (%) Positive (%)
Sex
Male 43 (71.67) 76.74 23.26 0.461
Female 17 (28.33) 82.35 17.65
Age, years
#66 23 (38.33) 78.26 21.74 0.617
>66 37 (61.67) 78.38 21.62
Clinical Stage
Early stage (IeII) 22 (36.67) 56.45 43.55 0.003*
Advanced stage (IIIeIV) 38 (63.33) 92.1 7.9
Distant metastasis
M0 46 (76.67) 86.79 13.21 <0.0001
M1 14 (23.33) 14.29 85.71
Tumour size
#5 cm 21 (35) 89.66 10.34 0.187
>5 cm 39 (65) 68.75 31.25
*Significant difference.
ESCC, oesophageal squamous cell carcinoma.
Figure 2 Hypermethylation in promoter region of miR-375 in
oesophageal squamous cell carcinoma (ESCC). (A) Methylation-specific
PCR (MSP) analysis of miR-375 promoter region in eight ESCC cell lines.
Methylated allele was detected in all ESCC cell lines while only
unmethylated allele was detected in N1 and N2. M, methylated allele; U,
unmethylated allele; N1, pool of non-tumour tissues from five ESCC; N2,
pool of blood lymphocytes from five healthy donors. (B) Bisulphite
genomic sequencing (BGS) of miR-375 promoter region in ESCC cell line
KYSE30, N1 and N2 (five clones for each sample). Each vertical bar
represents a CpG site. High densities of methylated CpG sites were
observed in KYSE30 but not in N1 and N2. Black and white circles
represent methylated and unmethylated CpG sites, respectively. (C)
Representative of methylation-specific PCR results of miR-375 in primary
ESCC. Methylation of miR-375 was detected in more than half (57.8%) of
the tumour specimens (upper panel). M, methylated allele; U,
unmethylated allele. The relative expression of miR-375 for each sample
was shown in the lower panel. SNORD48 was used as an internal
control. (D) Demethylation treatment with 5-aza-29-deoxycytidine (Aza)
could restore miR-375 expression in KYSE30 and KYSE510 cells.
SNORD48 was used as an internal control. 30 and 510, ESCC cell lines
KYSE30 and KYSE510 without treatment; aza 50, cell lines treated
with 50 µM 5-aza-29-deoxycytidine; aza 100, cell lines treated with
10 µM 5-aza-29-deoxycytidine.
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LNA array, miR-375 was strongly downregulated in ESCC cell
lines and primary ESCC samples from Hong Kong (figure 1B,C).
As Henan province is one of the ESCC high-risk areas in the
world, the expression of miR-375 was also investigated in 45
pairs of primary ESCC and corresponding non-tumour tissues
from Henan. Results showed that miR-375 was also significantly
downregulated in Henan ESCC samples (figure 1D).
Downregulation of miR-375 is associated with poor prognosis of
ESCC
To address the clinical significance of the downregulation of
miR-375 in ESCC, the correlation of miR-375 downregulation
with clinical-pathological features from 60 Hong Kong patients
was investigated. The results showed that the downregulation
of miR-375 was significantly correlated with advanced clinical
stage and distant metastasis while no significant correlation was
observed in other clinical-pathological parameters (table 2). To
investigate the prognostic significance of miR-375 in ESCC,
KaplaneMeier analysis was performed illustrating that low
miR-375 expression was associated with poorer overall survival
and disease-free survival in the ESCC cohort (figure 1E,F). These
results suggested that the downregulation of miR-375 may play
an important role in the development and progression of ESCC.
Downregulation of miR-375 is caused by promoter
hypermethylation
To understand the mechanism of miR-375 downregulation in
ESCC, the methylation status in the promoter region of miR-375
was tested. A previous report has indicated that the e768 bp
upstream of pre-miR-375 region contains promoter function.12 In
the present study, the promoter region was characterised by
methylation-specific PCR using methylation or unmethylation-
specific primers. In each of the eight ESCC cell lines in which the
downregulation of miR-375 was investigated, at least one allele
was methylated (figure 2A). In contrast, only the unmethylated
allele was detected in a pool of non-tumourous tissues (N1) and
a pool of peripheral blood lymphocytes from healthy donors
(N2) (figure 2A). In addition, BGS was used to characterise the
methylation details of miR-375 promoter in KYSE30, N1 and N2.
High densities of methylated CpG sites were only observed in
KYSE30 but not in N1 and N2 (figure 2B). To confirm further
that the promoter hypermethylation of miR-375 was the major
mechanism causing the downregulation of miR-375, 45 pairs of
primary ESCC tumours and the corresponding non-tumour
tissues from Henan were analysed by methylation-specific
PCR. Methylation of miR-375 was detected in 26 of 45
(57.8%) tumour specimens. The frequency of methylation was
noticeably higher in ESCC with miR-375 downregulation
(19/31, 61.3%) than that in ESCC with normal miR-375
expression (7/14, 50%) (figure 2C). To validate the result further,
KYSE30 and KYSE510 cells were treated with the demethylating
agent 5-aza-29-deoxycytidine. After the treatment, the expres-
sion of miR-375 was restored (figure 2D), indicating that
promoter hypermethylation was the major mechanism of the
downregulation of miR-375.
miR-375 suppresses tumour cell growth
To explore the potential tumour-suppressive role of miR-375 in
ESCC, miR-375 precursor was cloned and stably transfected into
Figure 3 miR-375 has a strong
tumour-suppressive effect. (A) Relative
expression of miR-375 was detected by
quantitative PCR in stably transfected
KYSE30 (KYSE30-375+) and KYSE510
(KYSE510-375+) cells relative to empty
vectors (KYSE30-vector or KYSE510-
vector). Expression was normalised
against an endogenous control
SNORD48. (B) miR-375 could inhibit the
foci formation ability of KYSE510-375+
cells. The results are expressed as
mean6SD of three independent
experiments. Vec, empty vector
KYSE510-vector; miR, stably transfected
clone KYSE510-miR375+. (C) Colony
formation in soft agar was significantly
inhibited by miR-375. The results are
expressed as mean6SD of three
independent experiments. (D) Cell
growth rates were suppressed by miR-
375 in KYSE30-375+ (left) and KYSE510-
375+ (right) detected by XTT assay. The
results are expressed as mean6SD of
three independent experiments.
*p<0.05. (E) Tumour growth curves
show that miR-375 could inhibit tumour
formation in nude mice induced by
KYSE30-375+ (left) and miR510 (right)
cells. Points and bars represent the mean
of five mice with SD. *p<0.05. For the
representatives of tumour formed in nude
mice, tumours were induced by empty
vector-transfected cells (left dorsal
flanks, indicated by arrows) and
miR-375-transfected cells (right dorsal
flanks), respectively.
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ESCC cell lines KYSE30 and KYSE510. The expression of mature
miR-375 in stable transfectants was confirmed by quantitative
PCR (figure 3A). Functional study showed that miR-375 could
suppress the foci formation (figure 3B) and colony formation in
soft agar (figure 3C) compared with empty vector-transfected
cells. XTT assay also showed that miR-375 could inhibit cell
growth rate (figure 3D). In addition, tumour formation in nude
mice was performed by injecting KYSE30-375+ cells (n¼5) or
KYSE510-375+ cells (n¼5), while KYSE30-vector or KYSE510-
vector cells were used as empty vector controls. Consistent with
in-vitro results, miR-375 could inhibit tumour formation in nude
mice (figure 3E). To detect the proliferating cells, immunohis-
tochemical staining of PCNA was performed. As expected, less
PCNA expression was observed in the KYSE30-375+ and
KYSE510-375+-derived tumours compared with KYSE30-vector
and KYSE510-vector-derived tumours (see supplementary figure
1, available online only). These results implied that miR-375 has
a strong ability to suppress tumour cell growth.
miR-375 suppresses ESCC invasion and metastasis
In addition to cell growth inhibition, the effect of miR-375 on
tumour invasion and metastasis was also addressed in this study.
Wound-healing assay showed that miR-375 could dramatically
suppress tumour cell mobility in KYSE30-375+ and KYSE510-
375+ cells compared with the empty vector-transfected cells
(figure 4A). To validate that mobility suppression is not caused
by the inhibitory effect of tumour cell growth, invasion assay
was also performed. The result demonstrated that miR-375 could
suppress the invasive ability of ESCC cells (figure 4B). To
investigate further the suppressive effect of miR-375 on tumour
metastasis, an experimental metastasis animal model was
performed by injecting KYSE30-375+ or KYSE510-375+ cells
into the tail vain of SCID mice (five mice per group). Empty
vector-transfected (KYSE30-vector or KYSE510-vector) cells
were used as controls (five mice per group). The mice were killed
and metastatic nodules were counted on the surface of liver after
12 weeks. The numbers of nodules formed in the liver induced
by KYSE30-375+ and KYSE510-375+ cells were significantly
more reduced than those induced by KYSE30-vector and
KYSE510-vector cells (figure 4C). Although no visible metastatic
nodule was observed on the surface of the lung, metastatic
lesions were detected in lung by haematoxylin and eosin
staining (figure 4D). These results indicated that miR-375 could
effectively suppress tumour metastasis in vitro and in vivo.
Figure 4 miR-375 suppresses tumour
metastasis. (A) Wound-healing assay
shows that cell motility could be
effectively suppressed by KYSE30-375
+ (left) and KYSE510-375+ (right).
Representative images were taken at
time 0, 24 and 48 h after scratching. (B)
miR-375 could successfully impede
tumour cell invasion in KYSE30 (left)
and KYSE510 (right) cells (p<0.001).
The results are expressed as mean6SD
of three independent experiments. (C)
miR-375 could suppress oesophageal
squamous cell carcinoma (ESCC)
metastasis in vivo. Representative
livers derived from severe combined
immunodeficient (SCID) mice in KYSE30
(left) and KYSE510 (right) are shown.
The formation of metastatic nodules at
the liver surface could be significantly
suppressed by KYSE30-375+ and
KYSE510-375+. (D) Metastatic
tumours in lung could be induced by
empty vector-transfected cells
(KYSE30-vector and KYSE510-vector) in
SCID mice, but not by miR-375-
transfected cells (KYSE30-375+ and
KYSE510-375+).
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IGF1R is the potential target of miR-375
As miR-375 inhibited tumour cell growth and metastasis, we
would like to investigate the potential target of miR-375. By
searching the potential targets of miR-375 with TargetScan,
pictar and miRanda, we compiled all the predicted genes for
functional clustering analysis classified by DAVID 6.7, Kegg and
Panther databases.13 Based on the method previously used by
other studies,14 15 IGF1R was identified as the target of miR-
375, which contains putative target sequence (figure 5A). To
validate the in-silico prediction, quantitative PCR and western
blotting were used to test whether the expression of IGF1R
could be repressed by miR-375. The result showed that miR-375
could downregulate IGF1R expression in both the mRNA level
(figure 5B) and protein level (figure 5C). Interestingly, mRNA
expression of IGF1R was negatively correlated with miR-375 in
ESCC cell lines (figure 5D). To validate whether IGF1R is the
direct downstream target of miR-375, a fragment of the 39-UTR
of IGF1R (301 bp) containing the potential miR-375 binding site
was cloned into a vector with the firefly luciferase reporter
gene. Luciferase activity was reduced by approximately 30%
compared with the control (figure 5E), which could be reversed
by treating culture cells with the antisense IGF1R 39-UTR
(figure 5E). This ensured the specificity of binding between
miR-375 and the 39-UTR of IGF1R. To investigate the correla-
tion between miR-375 and IGF1R in clinical specimens, quan-
titative PCR was performed to detect expressions of miR-375
and IGF1R in 60 primary ESCC samples from Hong Kong. The
expression of IGF1R was significantly higher in ESCC tumour,
compared with the corresponding non-tumour tissue (figure
5F). Moreover, a significant negative correlation was observed
between miR-375 and IGF1R (figure 5F). In addition, immu-
nohistochemical staining was applied to compare IGF1R
expression in tumours derived from nude mice injected with
KYSE30-vector or KYSE30-375+ using anti-IGF1R antibody.
The result showed that the expression of IGF1R was repressed
in KYSE30-375+-generated tumours, compared with KYSE30-
vector-generated tumours (see supplementary figure 2, available
online only), suggesting that the tumour-suppressive effect of
miR-375 was via suppressing IGF1R expression.
Knockdown of miR-375 increases tumour growth and metastasis
To confirm further the tumour-suppressive function of miR-375,
miR-375 was hindered by adding the specific inhibitor of miR-375
into the culture cells. As miR-375 was downregulated in all
Figure 5 Insulin-like growth factor 1
receptor (IGF1R) is a direct downstream
target of miR-375. (A) The predicted
binding sequence of human hsa-miR-375
and its binding site in the 39-untranslated
region (UTR) of IGF1R (sense) were
presented for alignment. Reverse-sense
was the reverse sequences of 39-UTR of
IGF1R without the binding sites of miR-
375. (B) Quantitative PCR result shows
that IGF1R could be downregulated by
miR-375 in KYSE30-375+ (left) and
KYSE510-375+ (right) cells (p<0.001).
Expression was normalised against an
endogenous control 18s rRNA and
results are expressed as mean6SD of
three independent experiments. (C)
Western blot analysis shows that miR-
375 could inhibit the protein expression
of IGF1R in KYSE30-375+ (left) and
KYSE510-375+ (right) cells. b-Actin
was used as an internal control. (D) The
expression of IGF1R was negatively
correlated with the miR-375 expression
level in eight oesophageal squamous cell
carcinoma (ESCC) cell lines. Expression
was shown in log10. 18s rRNA and
SNORD48 were used as internal controls
for IGF1R and miR-375 expression,
respectively. (E) Luciferase assay was
used to confirm the interaction of miR-
375 with IGF1R. 39-UTR of IGF1R
containing the target binding site (sense)
and the reverse sequences of 39-UTR of
IGF1R (reverse-sense) were cloned into
downstream of a firefly luciferase gene.
The plasmids (sense or reverse-sense)
were transfected into empty vector and
miR-375 stably expressing cells (miR-
375). Renilla luciferase plasmid was
co-transfected for normalisation. pGL3-Control vector was co-transfected as positive control. Control, positive control; +, plasmid added; , no plasmid
added. *p<0.05. (F) Expression level of IGF1R was tested in 60 primary ESCC from Hong Kong by quantitative PCR. Results showed that IGF1R was
frequently upregulated in tumour tissues (T) compared with their non-tumour counterparts (N) (left). 18s rRNA was used as an internal control. A
negative correlation between IGF1R and miR-375 expressions in 60 ESCC pairs from Hong Kong was determined with linear regression lines and Pearson
correlation significance (p¼0.008, Pearson correlation 0.25) (right).
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tested ESCC cell lines, miR-375 was knocked down in miR-375-
expressing clones. The silencing effect of miR-375 was confirmed
by quantitative PCR (figure 6A). Moreover, the expression of
IGF1R was restored after the miR-375 was inhibited (figure 6B).
XTTand foci formation assays also indicated that knockdown of
miR-375 could enhance the cell growth rate and increase foci
formation (figure 6C,D). In addition, tumour mobility and
invasive ability were also enhanced (figure 6E,F). Taken together,
these results indicated that tumour growth and metastasis was
enhanced after the knockdown of miR-375.
DISCUSSION
miRNA have been reported to play important roles in cancer
development and progression through repressing downstream
target genes.16 The first evidence to link miRNA and cancer came
from B-cell chronic lymphocytic leukaemia studies.17 Since then,
abnormal expressions of miRNA have been detected in different
types of cancers.18e20 However, little is known about the dysre-
gulation of miRNA in ESCC. For a better understanding of the
molecular mechanisms involved in the development and progres-
sion of ESCC, miRNA profiles between tumour and corresponding
non-tumour tissues from five primary ESCC cases were compared.
Twenty-two differentially expressed miRNA were detected.
Following this, we validated two most upregulated (miR-424 and
miR-422a) and two downregulated (miR-375 and miR-194) miRNA.
All of them have been associated with human cancers. For
example, miR-424 was upregulated in several cancers such as
colorectal cancer, tongue cancer, chronic myelogenous leukaemia
and renal cell carcinomas.21e24 One recent study showed that miR-
422a could be used as a diagnostic marker for osteosarcoma.25 The
role of miR-194 in cancer development is complicated. For instance,
some studies demonstrated that it is downregulated
in endometrioid endometrial cancer and ESCC.26 27 However,
different groups showed that miR-194 was upregulated in oeso-
phageal adenocarcinoma and prostate cancer.28 29 Due to the
largest absolute fold change, miR-375 was chosen for further study.
miR-375 has been reported to be important in the regulation of
insulin secretion.30 One study found that miR-375 is able to
suppress glucose-induced insulin secretion with no change in the
glucose-mediated production of ATP or intracellular calcium.31 The
downregulation of miR-375 has been reported in gastric cancer,32
hepatocellular carcinoma33 and head and neck cancer.34 However,
the function of miR-375 in ESCC remains unclear.
In the present study, we found that miR-375 was frequently
downregulated in primary ESCC cases from Hong Kong (n¼60)
and Henan (n¼45). Interestingly, the expression patterns of
miR-375 in both groups are very similar. Therefore, we assumed
that miR-375 plays a similar tumour-suppressing role in ESCC
development in both populations. The downregulation miR-375
was significantly associated with advanced clinical stage, distant
Figure 6 Knockdown of miR-375
enhanced tumour growth and
metastasis. (A) miR-375 inhibitor was
transiently transfected into KYSE30 and
KYSE510 using lipofectamine. Inhibition
was confirmed by quantitative PCR in
KYSE30-375e (left) and KYSE510-375e
(right). SNORD48 was used as an
internal control. *p<0.05 (B) The
expression of insulin-like growth factor
1 receptor (IGF1R) was increased after
knockdown of miR-375. *p<0.05. 18s
rRNA was used as an internal control.
(C) XTT assay showed that the
inhibition of miR-375 increased
oesophageal squamous cell carcinoma
(ESCC) cell growth. *p<0.05. (D) The
efficiency of foci formation was
enhanced after the suppression of miR-
375. *p<0.05. (E) Tumour cell motility
was enhanced after the repression of
miR-375. Representative images were
taken at time 0 h and 24 h after
scratching. (F) Cell invasive ability was
improved after the inhibition of miR-375.
The results are expressed as mean6SD
of three independent experiments.
*p<0.05.
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metastasis, poorer overall survival and poorer disease-free
survival in ESCC. Further study found that the mechanism of
miR-375 downregulation was closely associated with the
hypermethylation in its promoter region. The survival rate of
ESCC patients remains unsatisfactory despite advanced treat-
ments.35 Therefore, there is a great need to identify biomarkers
for the prediction of ESCC prognosis and to develop novel
therapeutic drugs for the improvement of ESCC patients’
survival. As the downregulation of miR-375 was correlated with
poorer survival of ESCC, miR-375 might be used as a prognostic
biomarker in ESCC.
In this study, the effects of miR-375 on ESCC development
and progression were also investigated by both in-vitro and in-
vivo assays. By transfecting miR-375 into ESCC cell lines
(KYSE30 and KYSE510), the expression of miR-375 could effec-
tively inhibit tumour cell growth rate, foci formation, colony
formation in soft agar and tumour formation in nude mice.
Furthermore, the expression of miR-375 could suppress tumour
cell motility and invasion. A metastasis experimental animal
model also confirmed that miR-375 could reduce the formation
of metastatic tumour nodules in liver and lung.
Each miRNA can potentially downregulate many target genes
through binding their 39-UTR. As the exact binding of miRNA
and target genes depend on cell types and microenvironment,
miRNA in different tissues or cancers may play different roles.17
One important task is to identify the downstream target genes
regulated by the dysregulated miRNA. By using DAVID Bioin-
formatics clustering tool (http://david.abcc.ncifcrf.gov/),13 one
candidate downstream target gene of miR-375, IGF1R, was iden-
tified. IGF1R is frequently overexpressed in many malignancies,
and plays a crucial role in promoting cell proliferation, survival
and metastasis.36 IGF1R has been shown to bind to the regulatory
subunit of phosphatidylinositol 3-kinase, PIK3R3, through the Src
homology 2 (SH2) domain and activate the phosphatidylinositol
3-kinase pathway.37 In the present study, quantitative PCR and
western blot analysis demonstrated that miR-375 could decrease
the expression of IGF1R in both mRNA and protein levels. In
addition, inhibiting miR-375 expression could increase IGF1R
expression. Luciferase assay showed that miR-375 could interact
with the 39-UTR of IGF1R. Moreover, the expression of IGF1R
was negatively correlated with miR-375 in clinical ESCC speci-
mens. These data strongly suggest that the tumour-suppressive
function of miR-375 is through the downregulation of IGF1R,
which may have a strong implication on the Akt pathway.
The identification and characterisation of the tumour-
suppressing effect of miR-375 may provide a novel therapeutic
target. A recent study showed that the delivery of tumour-
suppressive miRNA in mice could effectively suppress
tumourigenesis in liver cancer without causing toxicity,38 indi-
cating that a tumour-suppressive miRNA can be used as an
attractive approach for cancer treatment. In summary, we
demonstrated in this study that miR-375 is frequently down-
regulated in ESCC tumour cells, which is significantly associated
with poorer prognosis. The tumour-suppressing function of miR-
375 is through repressing its downstream target gene IGF1R, and
downregulation of miR-375 is one of the molecular mechanisms
leading to the development and progression of ESCC.
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